Enliven Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Enliven Therapeutics

14/03/2024 21:07

* Enliven Therapeutics Inc  ELVN.OQ  reported a quarterly
adjusted
loss of 47 cents​​ per share for the quarter ended in December. 
The mean expectation of four analysts for the quarter was for a
loss of 54 cents per share. Wall Street expected results to
range from -56 cents to -51 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Enliven Therapeutics Inc's reported EPS for the quarter
was a
loss of 47 cents​.
    * The company reported a quarterly loss of $19.37 million.
    * Enliven Therapeutics Inc shares had fallen by 11.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Enliven
Therapeutics Inc is $31.00 

This summary was machine generated from LSEG data March 14 at
09:06 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.54          -0.47          Beat
 Sep. 30 2023      -0.47          -0.51          Missed
 Jun. 30 2023      -0.36          -0.41          Missed
 Mar. 31 2023      -0.63          -0.80          Missed